Oppenheimer raised the firm’s price target on Edwards Lifesciences to $100 from $93 and keeps an Outperform rating on the shares. While the debate in transcatheter tricuspid valve therapies currently is focused on QoL and mortality, the firm contends that RV function longer-term might be the more credible metric to determine whether repair or replacement is the right approach in a large cohort of patients.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on EW:
- Early notable gainers among liquid option names on March 14th
- Micron upgraded, Foot Locker downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Buy at BofA after ‘bullish’ management meetings
- Edwards Lifesciences upgraded to Buy from Neutral at BofA
- Bad News for Edwards Lifesciences Corp. Stock: This New Risk Has Been Added
